WO1999007728A3 - Peptides lineaires derives de peptides antibiotiques, leur preparation et leur utilisation pour vectoriser des substances actives - Google Patents

Peptides lineaires derives de peptides antibiotiques, leur preparation et leur utilisation pour vectoriser des substances actives Download PDF

Info

Publication number
WO1999007728A3
WO1999007728A3 PCT/FR1998/001757 FR9801757W WO9907728A3 WO 1999007728 A3 WO1999007728 A3 WO 1999007728A3 FR 9801757 W FR9801757 W FR 9801757W WO 9907728 A3 WO9907728 A3 WO 9907728A3
Authority
WO
WIPO (PCT)
Prior art keywords
peptides
preparation
active substances
antibiotic
vectoring
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/FR1998/001757
Other languages
English (en)
Other versions
WO1999007728A2 (fr
Inventor
Bernard Calas
Gerard Grassy
Alain Chavanieu
Michel Kaczorek
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Synt EM SA
Original Assignee
Synt EM SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synt EM SA filed Critical Synt EM SA
Priority to EP98941556A priority Critical patent/EP1003771A1/fr
Priority to CA002298932A priority patent/CA2298932A1/fr
Priority to JP2000506230A priority patent/JP2001512739A/ja
Priority to IL13429398A priority patent/IL134293A0/xx
Priority to AU89889/98A priority patent/AU754617B2/en
Publication of WO1999007728A2 publication Critical patent/WO1999007728A2/fr
Publication of WO1999007728A3 publication Critical patent/WO1999007728A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6897—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies
    • A61K47/6898—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies using avidin- or biotin-conjugated antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Nanotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biochemistry (AREA)
  • Medical Informatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La présente invention concerne des peptides dérivés de peptides antibiotiques ou d'analogues de ceux-ci, caractérisés en ce qu'ils sont dépourvus de pont disulfure. L'invention concerne également l'utilisation de ces peptides linéaires pour la vectorisation de substances chimiques ainsi que les composés chimiques formés de ces peptides couplés à au moins une substance active. L'invention concerne encore la préparation de ces peptides et de ces composés et les compositions les contenant.
PCT/FR1998/001757 1997-08-12 1998-08-06 Peptides lineaires derives de peptides antibiotiques, leur preparation et leur utilisation pour vectoriser des substances actives Ceased WO1999007728A2 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP98941556A EP1003771A1 (fr) 1997-08-12 1998-08-06 Peptides lineaires derives de peptides antibiotiques, leur preparation et leur utilisation pour vectoriser des substances actives
CA002298932A CA2298932A1 (fr) 1997-08-12 1998-08-06 Peptides lineaires derives de peptides antibiotiques, leur preparation et leur utilisation pour vectoriser des substances actives
JP2000506230A JP2001512739A (ja) 1997-08-12 1998-08-06 抗生作用ペプチドから誘導される線状ペプチド、製法および活性物質を仲介する用途
IL13429398A IL134293A0 (en) 1997-08-12 1998-08-06 Linear peptides derived from antibiotic peptides, preparation and use for vectoring active substances
AU89889/98A AU754617B2 (en) 1997-08-12 1998-08-06 Linear peptides derived from antibiotic peptides, preparation and use for vectoring active substances

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR97/10297 1997-08-12
FR9710297A FR2767323B1 (fr) 1997-08-12 1997-08-12 Peptides lineaires derives de peptides antibiotiques, leur preparation et leur utilisation pour vectoriser des substances actives

Publications (2)

Publication Number Publication Date
WO1999007728A2 WO1999007728A2 (fr) 1999-02-18
WO1999007728A3 true WO1999007728A3 (fr) 1999-06-24

Family

ID=9510249

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR1998/001757 Ceased WO1999007728A2 (fr) 1997-08-12 1998-08-06 Peptides lineaires derives de peptides antibiotiques, leur preparation et leur utilisation pour vectoriser des substances actives

Country Status (7)

Country Link
EP (1) EP1003771A1 (fr)
JP (1) JP2001512739A (fr)
AU (1) AU754617B2 (fr)
CA (1) CA2298932A1 (fr)
FR (1) FR2767323B1 (fr)
IL (1) IL134293A0 (fr)
WO (1) WO1999007728A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10023615B2 (en) 2008-12-22 2018-07-17 Xigen Inflammation Ltd. Efficient transport into white blood cells

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2388991A1 (fr) * 1998-11-11 2001-04-19 Peter E. Nielsen Conjugues entre un peptide et un analogue d'acide nucleique tel que anp, anl ou une morpholine
DK173006B1 (da) * 1998-11-11 1999-11-01 Ke Burgmann As Fremgangsmåde og anlæg til frembringelse af vægmateriale til brug ved fremstilling af kompensatorer, navnlig til røggaskanaler, samt kompensatormateriale og kompensator frembragt ved fremgangsmåden
FR2786397B1 (fr) * 1998-11-30 2003-01-10 Synt Em Vecteurs peptidiques de substances a travers la barriere hematoencephalique pour etre utilises dans le diagnostic ou la therapie d'une affection du snc
FR2786398B1 (fr) * 1998-11-30 2002-12-27 Synt Em Composition pharmaceutique anti-cancereuse et anti-chimioresistance comprenant un agent anticancereux et au moins un peptide
US20040082509A1 (en) 1999-10-12 2004-04-29 Christophe Bonny Cell-permeable peptide inhibitors of the JNK signal transduction pathway
US8183339B1 (en) 1999-10-12 2012-05-22 Xigen S.A. Cell-permeable peptide inhibitors of the JNK signal transduction pathway
FR2810985B1 (fr) * 2000-07-03 2004-12-24 Synt Em Peptides lineaires amphipathiques et les compositions les contenant
GB0103110D0 (en) 2000-08-25 2001-03-28 Aventis Pharma Inc A membrane penetrating peptide encoded by a nuclear localization sequence from human period 1
JP4387669B2 (ja) 2000-10-13 2009-12-16 ザイジェン エス．アー． 新規なトランスポーターペプチド配列による生物学的エフェクターの細胞内送達
US7033597B2 (en) 2000-10-13 2006-04-25 Université de Lausanne Intracellular delivery of biological effectors
FR2821272B1 (fr) * 2001-02-23 2004-12-17 Synt Em Composes constitues d'une molecule analgesique liee a un vecteur capable de vectoriser ladite molecule a travers la barriere hematoencephalique et compositions pharmaceutiques les contenant
FR2829940A1 (fr) * 2001-09-27 2003-03-28 Synt Em Compositions pour la vectorisation d'anticorps a travers la barriere hematoencephalique et leur utilisation pour le diagnostic ou le traitement des maladies du systeme nerveux central
FR2830016B1 (fr) * 2001-09-27 2004-06-25 Synt Em Compositions pour la vectorisation de derives taxoides a travers la barriere hematoencephalique et leur utilisation pour le traitement des cancers, plus particulierement des cancers du cerveau
ES2282473T3 (es) * 2001-10-16 2007-10-16 Synt:Em S.A. Utilizacion de vectores peptidicos para mejorar la respuesta inmunitaria a antigenos.
FR2836474B1 (fr) * 2002-02-22 2004-12-24 Synt Em Composes, compositions et methode pour le transport des molecules de cyclosporine a travers la barriere hemato-encephalique
FR2840810B1 (fr) * 2002-06-18 2005-02-11 Synt Em Composition pour le transfert de molecules therapeutiques dans les poumons et leur utilisation pour le traitement des cancers du poumon et des maladies pulmonaires
WO2007031098A1 (fr) 2005-09-12 2007-03-22 Xigen S.A. Inhibiteurs peptidiques permeables aux cellules de la voie de transduction de signal jnk
US8080517B2 (en) 2005-09-12 2011-12-20 Xigen Sa Cell-permeable peptide inhibitors of the JNK signal transduction pathway
FR2914928B1 (fr) * 2007-04-12 2009-07-10 Univ Victor Segalen Bordeaux 2 Procede de preparation d'un support pour l'immobilisation d'une cellule, ledit support et ses utilisations
WO2009143864A1 (fr) 2008-05-30 2009-12-03 Xigen S.A. Utilisation d'inhibiteurs peptidiques perméables aux cellules de la voie de transduction du signal jnk pour le traitement de maladies digestives inflammatoires chroniques ou non chroniques
WO2009143865A1 (fr) 2008-05-30 2009-12-03 Xigen S.A. Utilisation d'inhibiteurs peptidiques des voies de traduction du signal jnk perméables aux cellules pour le traitement de diverses maladies
EP3168231A1 (fr) 2008-06-12 2017-05-17 Centre for Addiction and Mental Health Compositions et procédés de modulation d'interaction et de fonction du récepteur de dopamine d1-d2
WO2011160653A1 (fr) 2010-06-21 2011-12-29 Xigen S.A. Nouvelles molécules inhibant jnk
US9150618B2 (en) 2010-10-14 2015-10-06 Xigen Inflammation Ltd. Use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of chronic or non-chronic inflammatory eye diseases
WO2013091670A1 (fr) 2011-12-21 2013-06-27 Xigen S.A. Nouvelles molécules inhibitrices de jnk pour le traitement de diverses maladies
WO2014206427A1 (fr) 2013-06-26 2014-12-31 Xigen Inflammation Ltd. Nouvelle utilisation d'inhibiteurs de peptides à perméabilité cellulaire dans la voie de transduction du signal jnk pour le traitement de diverses maladies
WO2014206563A2 (fr) 2013-06-26 2014-12-31 Xigen Inflammation Ltd. Nouvelle utilisation d'inhibiteurs peptidiques perméables aux cellules de la voie de transduction du signal jnk pour le traitement de diverses maladies
WO2015197097A1 (fr) 2014-06-26 2015-12-30 Xigen Inflammation Ltd. Nouvelle utilisation pour des molécules inhibitrices de la jnk, pour le traitement de diverses maladies

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990004408A1 (fr) * 1988-10-21 1990-05-03 Magainin Sciences, Inc. Composition et traitement a l'aide de peptides a activite biologique et certains anions
WO1994018323A1 (fr) * 1993-02-02 1994-08-18 Xoma Corporation Produits proteiniques stables bactericides ou renforçant la permeabilite et compositions pharmaceutiques les contenant
WO1995016776A1 (fr) * 1993-12-17 1995-06-22 Pioneer Hi-Bred International, Inc. Derives de la tachyplesine presentant une activite inhibitrice vis a vis des champignons pathogenes vegetaux
WO1996037508A1 (fr) * 1995-05-26 1996-11-28 University Of California, Los Angeles Protegrines
WO1997018826A1 (fr) * 1995-11-22 1997-05-29 Intrabiotics Pharmaceuticals, Inc. Protegrines finement mises au point

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2151046A1 (fr) * 1992-12-07 1994-06-23 Mukta Hendi Traitement de choc septique grace a des peptides conjugues biologiquement actifs
US5756462A (en) * 1994-01-19 1998-05-26 Pfizer Inc. Pore forming peptides from Geolycosa riogrande
EP0952841A4 (fr) * 1994-08-05 2000-11-02 Molecular Structural Biotechno Complexes biomoleculaires diriges
US5688489A (en) * 1995-09-15 1997-11-18 Resolution Pharmaceuticals, Inc. Non-receptor mediated imaging agents
KR100454366B1 (ko) * 1995-11-16 2005-04-28 셀 인터나쵸나아레 레사아치 마아츠샤피 비이부이 가교결합성하이드록시작용성폴리디엔중합체코팅조성물및이의제조방법

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990004408A1 (fr) * 1988-10-21 1990-05-03 Magainin Sciences, Inc. Composition et traitement a l'aide de peptides a activite biologique et certains anions
WO1994018323A1 (fr) * 1993-02-02 1994-08-18 Xoma Corporation Produits proteiniques stables bactericides ou renforçant la permeabilite et compositions pharmaceutiques les contenant
WO1995016776A1 (fr) * 1993-12-17 1995-06-22 Pioneer Hi-Bred International, Inc. Derives de la tachyplesine presentant une activite inhibitrice vis a vis des champignons pathogenes vegetaux
WO1996037508A1 (fr) * 1995-05-26 1996-11-28 University Of California, Los Angeles Protegrines
WO1997018826A1 (fr) * 1995-11-22 1997-05-29 Intrabiotics Pharmaceuticals, Inc. Protegrines finement mises au point

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
MASUDA, MASAO ET AL: "A novel anti-HIV synthetic peptide, T-22 ([Tyr5,12, Lys7]-polyphemusin II)", BIOCHEM. BIOPHYS. RES. COMMUN. (1992), 189(2), 845-50 CODEN: BBRCA9;ISSN: 0006-291X, 1992, XP002065781 *
QU, XIAO-DAN ET AL: "Protegrin structure and activity against Neisseria gonorrhoeae", INFECT. IMMUN. (1997), 65(2), 636-639 CODEN: INFIBR;ISSN: 0019-9567, 1997, XP002065780 *
TAMAMURA, HIROKAZU ET AL: "Antimicrobial activity and conformation of tachyplesin I and its analogs", CHEM. PHARM. BULL. (1993), 41(5), 978-80 CODEN: CPBTAL;ISSN: 0009-2363, 1993, XP002047195 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10023615B2 (en) 2008-12-22 2018-07-17 Xigen Inflammation Ltd. Efficient transport into white blood cells

Also Published As

Publication number Publication date
AU754617B2 (en) 2002-11-21
WO1999007728A2 (fr) 1999-02-18
AU8988998A (en) 1999-03-01
IL134293A0 (en) 2001-04-30
FR2767323A1 (fr) 1999-02-19
EP1003771A1 (fr) 2000-05-31
JP2001512739A (ja) 2001-08-28
CA2298932A1 (fr) 1999-02-18
FR2767323B1 (fr) 2001-01-05

Similar Documents

Publication Publication Date Title
IL142531A0 (en) Cyclic peptide compound, processes for the preparation thereof and pharmaceutical compositions containing the same
ZA979550B (en) Method for the preparation of methylidene malonate nanoparticles, nanoparticles which optionally contain one or more biologically active molecules, and pharmaceutical compositions containing them.
WO1998022136A3 (fr) Preparations pharmaceutiques lyophilisees stables d'anticorps monoclonaux ou polyclonaux
ZA988585B (en) Pharmaceutical compositions containing plasma protein.
WO1998038984A3 (fr) Preparations d'agents pharmaceutiques hydrophobes
TR200100366T2 (tr) Aktif madde dağıtmaya mahsus bileşikler ve bileşimler.
IL136938A0 (en) 11β-HALOGEN-7α-SUBSTITUTED ESTRATRIENES, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AND METHODS FOR THE PREPARATION THEREOF
GEP20104997B (en) Composition comprising anther2 antibodies
CA2326137A1 (fr) Procede de stabilisation de compositions pharmaceutiques par utilisation speciale d'un antioxydant
IL138280A0 (en) 20-KETO-11β-ARYLSTERIODS, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AND METHODS FOR THE PREPARATION THEREOF
IL106600A0 (en) Peptides,pharmaceutical compositions containing the same and processes for the preparation thereof
IL140897A0 (en) Benzocycloheptene derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
IL137494A0 (en) Polypeptide compounds, process for the preparation thereof and pharmaceutical compositions containing the same
CA2355618A1 (fr) Suspensions de polyol/huile assurant la liberation prolongee des proteines
AU1934495A (en) Formulations for il-11
IL134293A0 (en) Linear peptides derived from antibiotic peptides, preparation and use for vectoring active substances
TR200001012T2 (tr) Yeni ariloksi-alkil-dialkilaminler.
CA2335551A1 (fr) Analogues des hormones thyroidiennes et methodes de preparation associees
AU8988098A (en) Vectors derived from antibodies for transferring substances into cells
ZA995201B (en) Stabilized protein compositions.
ZA974984B (en) New substituted thiazolidine-2,4-dione derivatives, processes for the obtaining thereof, and pharmaceutical compositions containing them.
HUP0102671A3 (en) Immunosupressive pharmaceutical compositions containing 2',2'-difluoro-nucleoside analogues
EP1140097A4 (fr) Produits contenant des trihydroxystilbenes et leurs derives, leurs procedes de production et leur utilisation
AU5892399A (en) 1, 2, 4-triazole-3-thione compounds
WO2000076528A3 (fr) Preparation pharmaceutique

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 134293

Country of ref document: IL

AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

ENP Entry into the national phase

Ref document number: 2298932

Country of ref document: CA

Ref country code: CA

Ref document number: 2298932

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 89889/98

Country of ref document: AU

NENP Non-entry into the national phase

Ref country code: KR

WWE Wipo information: entry into national phase

Ref document number: 1998941556

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1998941556

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 09485571

Country of ref document: US

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWG Wipo information: grant in national office

Ref document number: 89889/98

Country of ref document: AU